Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1

Eastern Hepatobiliary Surgery Hospital320 enrolled

Overview

In order to provide a new option for clinical anti-angiogenesis therapy in hepatoma, a randomized controlled study is planed to confirm the effect of Rg3 in combination with TACE on angiogenesis and tumor treatment in advanced hepatocellular carcinoma patients with high expression of Notch1.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

320

Conditions

Hepatocellular Carcinoma TACE Notch1 Rg3

Interventions

TACEPROCEDURE

iodized oil (5ml) + Pirarubicin (20mg)

Rg3DRUG

20mg, BID, maintained though Month 12.

TACE + Rg3OTHER

protective therapyPROCEDURE

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Pathologically confirmed hepatocellular carcinoma. 2. High expression of Notch1 in tumor tissues. Exclusion Criteria: no pathological evidence of HCC

Locations (1)

Eastern hepatobilliary surgery hospital

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

Overall Survival

Time frame: 3 years

Time to progression

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.